臺灣博碩士論文加值系統

目錄
指導教授推薦書.........................................................
口試委員會審定書.......................................................
誌謝...................................................................iii
中文摘要...............................................................iv
英文摘要...............................................................v
目錄...................................................................vi
圖目錄.................................................................ix
第一章 背景介紹........................................................1
1.1 腫瘤微環境.......................................................1
1.2 血管新生及腫瘤生長...............................................1
1.3 腫瘤促血管新生的浸潤細胞種類.....................................2
1.4 趨化因子CCL3.....................................................4
1.5 抗血管新生治療...................................................5
1.6 EBV及其致癌基因LMP1..............................................5
1.7 N-LMP1腫瘤動物模式及前人研究.....................................7
第二章 研究目的和策略..................................................8
第三章 實驗方法........................................................9
3.1 實驗所用之小鼠...................................................9
3.2 EBV-NLMP1 mouse tumor model......................................9
3.3 TSC preparation..................................................10
3.4 Flow cytometic analysis..........................................10
3.5 In vitro tube formation assay....................................10
3.6 In vitro neutralize antibody assay...............................11
3.7 In vivo matrigel assay...........................................12
第四章 實驗結果........................................................13
4.1 腫瘤組織的初期血管...............................................13
4.2 腫瘤組織初期細胞組成鑑定.........................................13
4.3 In vitro tube formation assay初步測試............................14
4.4 In vitro tube formation assay細胞數和觀察時間測試................15
4.5 單純TSC未能在in vitro tube formation assay中有結果...............15
4.6 TSC和周圍包覆的脂肪組織中的細胞共同培養..........................16
4.7 TSC聚集的原因....................................................16
4.8 BMDC對聚集的重要性...............................................17
4.9 腫瘤細胞在聚集中的分布...........................................17
4.10 TSC於in vitro tube formation assay系統中的發展..................18
4.11 聚集的大小和類絲狀結構的關聯....................................19
4.12 In vitro下聚集中促使類絲狀結構產生的關鍵分子....................20
4.13 以in vivo活體確認對血管新生具關鍵影響的分子.....................21
第五章 討論............................................................23
參考文獻...............................................................30
附錄.............................................................35

圖目綠
圖1. 利用流式細胞分析技術分析第7天TSC細胞的組成與特性...............35
圖2. CD31+細胞培養第10天之結果......................................37
圖3. In vitro tube formation assay細胞數的測試......................38
圖4. TSC在有無脂肪組織細胞共同培養的情形............................39
圖5. Medium與matrigel對E2+腫瘤細胞株聚集之影響......................40
圖6. BMDC的有無對TSC形成聚集的影響..................................41
圖7. 腫瘤細胞在聚集中的分布情形.....................................42
圖8. TSC產生聚集及聚集隨天數變化之情形..............................43
圖9. 聚集隨天數變化之情形...........................................44
圖10. 聚集數量隨天數變化之情形......................................45
圖11. 聚集依面積之分布情形..........................................46
圖12. 具類絲狀結構之聚集依面積之分布情形............................47
圖13. In vitro下聚集中促使類絲狀結構產生的關鍵分子..................48
圖14. TSC alone matrigel 的H&E染色結果..............................49
圖15. Matrigel alone H&E染色結果....................................51
圖16. TSC with mouse IgG1 antibody matrigel H&E染色結果.............52
圖17. TSC with rat IgG2b antibody matrigel H&E染色結果..............54
圖18. TSC with hamster IgG antibody matrigel H&E染色結果............55
圖19. TSC with VEGFR1 antibody matrigel H&E染色結果.................56
圖20. TSC with c-Kit antibody matrigel H&E染色結果..................57
圖21. TSC with CCL3 antibody matrigel H&E染色結果...................58
圖22. TSC with CD61 antibody matrigel H&E染色結果...................59
圖23. TSC with CD31 antibody matrigel H&E染色結果...................60

1. Joyce, J. A.Pollard, J. W. (2009) Microenvironmental regulation of metastasis. Nature reviews. Cancer 9:239-252.
2. Cretu, A.Brooks, P. C. (2007) Impact of the non-cellular tumor microenvironment on metastasis: potential therapeutic and imaging opportunities. J Cell Physiol 213:391-402.
3. Bergers, G.Benjamin, L. E. (2003) Tumorigenesis and the angiogenic switch. Nature reviews. Cancer 3:401-410.
4. Carmeliet, P.Jain, R. K. (2000) Angiogenesis in cancer and other diseases. Nature 407:249-257.
5. Bergers, G.Benjamin, L. E. (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401-410.
6. Al-Jamal, K. T., Al-Jamal, W. T., Akerman, S., Podesta, J. E., Yilmazer, A., Turton, J. A., Bianco, A.et al (2010) Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth. Proc Natl Acad Sci U S A 107:3966-3971.
7. Albini, A.Sporn, M. B. (2007) The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 7:139-147.
8. Greenfield, J. P., Cobb, W. S.Lyden, D. (2010) Resisting arrest: a switch from angiogenesis to vasculogenesis in recurrent malignant gliomas. J Clin Invest 120:663-667.
9. Asahara, T., Masuda, H., Takahashi, T., Kalka, C., Pastore, C., Silver, M., Kearne, M.et al (1999) Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circulation research 85:221-228.
10. Takahashi, T., Kalka, C., Masuda, H., Chen, D., Silver, M., Kearney, M., Magner, M.et al (1999) Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 5:434-438.
11. Asahara, T., Takahashi, T., Masuda, H., Kalka, C., Chen, D., Iwaguro, H., Inai, Y.et al (1999) VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 18:3964-3972.
12. Neufeld, G., Cohen, T., Gengrinovitch, S.Poltorak, Z. (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13:9-22.
13. Adams, R. H.Alitalo, K. (2007) Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 8:464-478.
14. Ferrara, N., Gerber, H. P.LeCouter, J. (2003) The biology of VEGF and its receptors. Nature medicine 9:669-676.
15. Edling, C. E.Hallberg, B. (2007) c-Kit--a hematopoietic cell essential receptor tyrosine kinase. Int J Biochem Cell Biol 39:1995-1998.
16. Roskoski, R., Jr. (2005) Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor. Biochem Biophys Res Commun 337:1-13.
17. Takakura, N., Watanabe, T., Suenobu, S., Yamada, Y., Noda, T., Ito, Y., Satake, M.et al (2000) A role for hematopoietic stem cells in promoting angiogenesis. Cell 102:199-209.
18. Ilan, N., Mahooti, S., Rimm, D. L.Madri, J. A. (1999) PECAM-1 (CD31) functions as a reservoir for and a modulator of tyrosine-phosphorylated beta-catenin. J Cell Sci 112 Pt 18:3005-3014.
19. Dejana, E. (2004) Endothelial cell-cell junctions: happy together. Nat Rev Mol Cell Biol 5:261-270.
20. Privratsky, J. R., Paddock, C. M., Florey, O., Newman, D. K., Muller, W. A.Newman, P. J. (2011) Relative contribution of PECAM-1 adhesion and signaling to the maintenance of vascular integrity. J Cell Sci 124:1477-1485.
21. Avraamides, C. J., Garmy-Susini, B.Varner, J. A. (2008) Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 8:604-617.
22. Brooks, P. C., Clark, R. A.Cheresh, D. A. (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264:569-571.
23. Mahabeleshwar, G. H., Feng, W., Phillips, D. R.Byzova, T. V. (2006) Integrin signaling is critical for pathological angiogenesis. J Exp Med 203:2495-2507.
24. Taverna, D., Moher, H., Crowley, D., Borsig, L., Varki, A.Hynes, R. O. (2004) Increased primary tumor growth in mice null for beta3- or beta3/beta5-integrins or selectins. Proc Natl Acad Sci U S A 101:763-768.
25. Wu, Y., Li, Y. Y., Matsushima, K., Baba, T.Mukaida, N. (2008) CCL3-CCR5 axis regulates intratumoral accumulation of leukocytes and fibroblasts and promotes angiogenesis in murine lung metastasis process. J Immunol 181:6384-6393.
26. Chung, A. S., Lee, J.Ferrara, N. (2010) Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 10:505-514.
27. Grepin, R.Pages, G. (2010) Molecular mechanisms of resistance to tumour anti-angiogenic strategies. J Oncol 2010:835680.
28. Gunven, P., Klein, G., Henle, G., Henle, W.Clifford, P. (1970) Epstein-Barr virus in Burkitt's lymphoma and nasopharyngeal carcinoma. Antibodies to EBV associated membrane and viral capsid antigens in Burkitt lymphoma patients. Nature 228:1053-1056.
29. Thompson, M. P.Kurzrock, R. (2004) Epstein-Barr virus and cancer. Clin Cancer Res 10:803-821.
30. Hao, S. P., Tsang, N. M.Chang, K. P. (2003) Screening nasopharyngeal carcinoma by detection of the latent membrane protein 1 (LMP-1) gene with nasopharyngeal swabs. Cancer 97:1909-1913.
31. Nakamura, H., Ishii, C., Suehiro, M., Iguchi, A., Kuroda, K., Shimizu, K., Shimizu, N.et al (2008) The latent membrane protein 1 (LMP1) encoded by Epstein-Barr virus induces expression of the putative oncogene Bcl-3 through activation of the nuclear factor-kappaB. Virus Res 131:170-179.
32. Li, H. P.Chang, Y. S. (2003) Epstein-Barr virus latent membrane protein 1: structure and functions. J Biomed Sci 10:490-504.
33. Li, S. N., Chang, Y. S.Liu, S. T. (1996) Effect of a 10-amino acid deletion on the oncogenic activity of latent membrane protein 1 of Epstein-Barr virus. Oncogene 12:2129-2135.
34. Chow, K. P., Wu, C. C., Chang, H. Y., Chang, C.Chang, Y. S. (2008) A simplified tumour model established via Epstein-Barr virus-encoded, nasopharyngeal carcinoma-derived oncogene latent membrane protein 1 in immunocompetent mice. Lab Anim 42:193-203.
35. Sathy, B. N., Chou, Y. H., Li, H. J., Chang, C.Chow, K. P. (2009) Dynamic contrast-enhanced and T2-weighted magnetic resonance imaging study of the correlation between tumour angiogenesis and growth kinetics. Lab Anim 43:53-59.
36. Chen, M. L., Tsai, C. N., Liang, C. L., Shu, C. H., Huang, C. R., Sulitzeanu, D., Liu, S. T.et al (1992) Cloning and characterization of the latent membrane protein (LMP) of a specific Epstein-Barr virus variant derived from the nasopharyngeal carcinoma in the Taiwanese population. Oncogene 7:2131-2140.
37. Louvet, C., Szot, G. L., Lang, J., Lee, M. R., Martinier, N., Bollag, G., Zhu, S.et al (2008) Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A 105:18895-18900.
38. Chacko, A. M., Nayak, M., Greineder, C. F., Delisser, H. M.Muzykantov, V. R. (2012) Collaborative enhancement of antibody binding to distinct PECAM-1 epitopes modulates endothelial targeting. PLoS One 7:e34958.
39. Chidlow, J. H., Jr., Glawe, J. D., Alexander, J. S.Kevil, C. G. (2010) VEGF(1)(6)(4) differentially regulates neutrophil and T cell adhesion through ItgaL- and ItgaM-dependent mechanisms. Am J Physiol Gastrointest Liver Physiol 299:G1361-1367.
40. Sakala, I. G., Eickhoff, C. S., Blazevic, A., Moheno, P., Silver, R. F.Hoft, D. F. (2013) Dipterinyl calcium pentahydrate inhibits intracellular mycobacterial growth in human monocytes via the C-C chemokine MIP-1beta and nitric oxide. Infect Immun 81:1974-1983.
41. Yamaji, D., Na, R., Feuermann, Y., Pechhold, S., Chen, W., Robinson, G. W.Hennighausen, L. (2009) Development of mammary luminal progenitor cells is controlled by the transcription factor STAT5A. Genes Dev 23:2382-2387.
42. 曾媺輪 (2011) Infiltration of bone marrow-derived cell in tumor leaky vasculature. 長庚大學生物醫學研究所微生物組碩士論文.
43. Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J.et al (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121:335-348.
44. 洪子原 (2011) The bioluminescence imaging of in vivo metastasis of mouse subcutaneous implanted tumor. 長庚大學生物醫學研究所微生物組碩士論文.
45. LeCouter, J., Moritz, D. R., Li, B., Phillips, G. L., Liang, X. H., Gerber, H. P., Hillan, K. J.et al (2003) Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 299:890-893.
46. Matsumoto, T.Claesson-Welsh, L. (2001) VEGF receptor signal transduction. Sci STKE 2001:re21.
47. Park, J. E., Chen, H. H., Winer, J., Houck, K. A.Ferrara, N. (1994) Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 269:25646-25654.
48. Kidd, S., Spaeth, E., Watson, K., Burks, J., Lu, H., Klopp, A., Andreeff, M.et al (2012) Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS One 7:e30563.
49. Kaufman, D. S., Hanson, E. T., Lewis, R. L., Auerbach, R.Thomson, J. A. (2001) Hematopoietic colony-forming cells derived from human embryonic stem cells. Proc Natl Acad Sci U S A 98:10716-10721.
50. Hill, J. M., Zalos, G., Halcox, J. P., Schenke, W. H., Waclawiw, M. A., Quyyumi, A. A.Finkel, T. (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348:593-600.
51. Rohde, E., Bartmann, C., Schallmoser, K., Reinisch, A., Lanzer, G., Linkesch, W., Guelly, C.et al (2007) Immune cells mimic the morphology of endothelial progenitor colonies in vitro. Stem Cells 25:1746-1752.
52. Hirschi, K. K., Ingram, D. A.Yoder, M. C. (2008) Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol 28:1584-1595.
53. Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B.et al (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964-967.
54. Schmeisser, A., Garlichs, C. D., Zhang, H., Eskafi, S., Graffy, C., Ludwig, J., Strasser, R. H.et al (2001) Monocytes coexpress endothelial and macrophagocytic lineage markers and form cord-like structures in Matrigel under angiogenic conditions. Cardiovasc Res 49:671-680.
55. Shih, Y. Y., Hsu, Y. H., Duong, T. Q., Lin, S. S., Chow, K. P.Chang, C. (2011) Longitudinal study of tumor-associated macrophages during tumor expansion using MRI. NMR Biomed 24:1353-1360.
56. Reynolds, L. E., Wyder, L., Lively, J. C., Taverna, D., Robinson, S. D., Huang, X., Sheppard, D.et al (2002) Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med 8:27-34.
57. Li, Y., Zhang, F., Nagai, N., Tang, Z., Zhang, S., Scotney, P., Lennartsson, J.et al (2008) VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats. J Clin Invest 118:913-923.
58. Mekori, Y. A., Oh, C. K.Metcalfe, D. D. (1995) The role of c-Kit and its ligand, stem cell factor, in mast cell apoptosis. Int Arch Allergy Immunol 107:136-138.
59. Reynolds, A. R., Hart, I. R., Watson, A. R., Welti, J. C., Silva, R. G., Robinson, S. D., Da Violante, G.et al (2009) Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 15:392-400.
60. Robinson, S. D.Hodivala-Dilke, K. M. (2011) The role of beta3-integrins in tumor angiogenesis: context is everything. Curr Opin Cell Biol 23:630-637